Brent Ahrens is a General Partner with the Canaan Partners, an early stage Life Sciences and IT venture capital fund. Prior to his tenure at Canaan, Mr. Ahrens worked for GSI, where he managed business development, marketing and sales efforts. In addition to his experience at GSI, he also worked for the Ethicon Endo-Surgery division of Johnson & Johnson, where he was involved in product development and at IAP Research as a Senior Research Engineer.
Mr. Ahrens is the holder of three patents relating to medical technologies. He also sits on the boards of Coapt Systems, CoAxia, Novare Surgical Systems, Pavad Medical, Relievant Medsystems, and other private boards.
Brent earned a BS and MS in mechanical engineering from the University of Dayton and an MBA from the Tuck School of Business at Dartmouth College. In 2007, Brent was included on the Forbes Midas List, which ranks the best dealmakers in technology and life sciences. He is also an alumnus of the Kauffman Fellows Program, an educational program designed to identify, develop and network future leaders of the global venture capital industry.
General Partner at Canaan Partners
1999 - Current (over 17 years)
|Mar 24, 2016||PRNewswire All - Iterum Therapeutics Licenses Global Rights to Novel Anti-Infective Compound|
|Jul 7, 2015||Business Wire - Biothera Pharmaceutical Inc. Announces Board of Directors|
|Apr 10, 2014||FinSMEs - FinSMEs|
|Mar 28, 2013||FinSMEs - FinSMEs|
|Jan 9, 2012||Xconomy - Canaan Partners Survives VC Turmoil, Raises New $600M Tech/Biotech Fund|
|Feb 2, 2010||TechCrunch - TheFunded Ranks The Most Loved VCs Of 2009|
|May 3, 2005||Venture Beat - Canaan rakes more money into valley|